Last updated: October 8, 2026
PRIMACOR in 5% dextrose is a premixed intravenous formulation of milrinone lactate, a phosphodiesterase-3 inhibitor used for short-term treatment of acute decompensated heart failure. Its commercial position is mature and largely genericized. The product has limited standalone financial visibility because manufacturers generally report milrinone within broader hospital injectable portfolios rather than as a separate revenue line.
The principal commercial drivers are hospital demand, intensive-care utilization, generic competition, supply reliability, and contract pricing. Patent risk is low for the active ingredient and conventional premixed formulation. The main barriers to competition are manufacturing controls, sterile fill-finish capacity, FDA approval requirements, hospital contracting, and periodic injectable-drug shortages.
What is PRIMACOR in Dextrose 5%?
PRIMACOR in Dextrose 5% is a ready-to-use intravenous infusion containing milrinone lactate in a 5% dextrose solution. The formulation is supplied in a plastic container and is intended for controlled intravenous administration after dilution or infusion-system preparation according to labeling.
Milrinone increases cardiac contractility and produces vasodilation through phosphodiesterase-3 inhibition. It is used primarily in acute-care settings, including intensive-care units and cardiac-care environments. It is not a chronic outpatient heart-failure product.
| Product attribute |
Description |
| Brand |
PRIMACOR |
| Active ingredient |
Milrinone lactate |
| Dosage form |
Intravenous injection or infusion solution |
| Premixed vehicle |
Dextrose 5% |
| Container |
Flexible plastic intravenous container |
| Therapeutic class |
Phosphodiesterase-3 inhibitor; inotrope and vasodilator |
| Primary setting |
Hospital and intensive-care use |
| Typical commercial channel |
Institutional purchasing and group purchasing organizations |
| FDA pathway |
New drug application for the branded product; abbreviated new drug applications for generic versions |
FDA labeling identifies milrinone lactate injection as a short-term treatment option for patients with acute decompensated heart failure, while also warning about risks including ventricular arrhythmias, hypotension, and accumulation in renal impairment (U.S. Food and Drug Administration [FDA], n.d.-a).
What is the market status of PRIMACOR in Dextrose 5%?
The product operates in a mature hospital injectable market rather than a branded specialty-pharmaceutical market. Brand recognition remains relevant in clinical terminology, but purchasing decisions are generally based on approved generic equivalence, price, availability, container configuration, and vendor reliability.
The branded PRIMACOR presentation has limited current commercial differentiation from generic milrinone lactate injection in dextrose. Hospitals can source the same active ingredient through generic injectable suppliers, although exact presentation, concentration, container size, and premixed status may differ.
The market is shaped by four factors:
- Acute-care demand is relatively stable but tied to hospital admissions and intensive-care utilization.
- The product is administered under medical supervision, limiting retail substitution dynamics.
- Generic competition compresses unit prices.
- Manufacturing disruptions can create temporary pricing and allocation pressure.
The product is therefore best characterized as a low-growth, low-price, supply-sensitive institutional medicine.
What competing products are available?
Competition includes generic milrinone lactate injection supplied in vials, ampules, syringes, and premixed intravenous containers. Depending on the market and date, suppliers may include Baxter, Hikma Pharmaceuticals, Pfizer or Hospira-related entities, Fresenius Kabi, and other FDA-approved injectable manufacturers.
Exact supplier participation changes as companies discontinue presentations, enter or leave shortage markets, or alter container configurations. A hospital may consider a vial-based product substitutable from an active-ingredient perspective while still preferring a premixed bag to reduce compounding labor and medication-error risk.
How large is the PRIMACOR market?
Public sources do not disclose a reliable standalone global or U.S. revenue figure for PRIMACOR in Dextrose 5% plastic containers. Sanofi’s public financial reporting has not historically separated this product from its broader pharmaceutical portfolio, and generic manufacturers also generally aggregate milrinone sales within hospital injectable or established-products categories.
A practical market model is based on product characteristics rather than reported brand revenue:
| Market variable |
Expected effect on PRIMACOR economics |
| Hospital admissions |
Supports baseline demand |
| Intensive-care utilization |
Increases demand for injectable inotropes |
| Generic entry |
Reduces average selling price |
| Premixed-container availability |
Supports operational value and purchasing preference |
| Drug shortages |
Can raise short-term price and increase substitution |
| GPO contracting |
Reduces supplier margins |
| Sterile manufacturing capacity |
Limits supply flexibility |
| Cardiovascular treatment trends |
Can reduce or redirect use over time |
Demand is relatively inelastic during acute cardiovascular episodes, but procurement demand is price-sensitive because hospitals typically maintain approved alternatives. A manufacturer with reliable supply can retain share even when its price is not the lowest, particularly when competitors experience backorders.
What is the financial trajectory for PRIMACOR?
The financial trajectory is consistent with an older, genericized hospital product:
- Historical branded revenue likely declined after loss of meaningful market exclusivity and generic availability.
- Current brand-specific revenue is likely limited relative to the product’s historical commercial contribution.
- Generic suppliers compete for recurring institutional volume at lower prices.
- Revenue can fluctuate sharply during supply interruptions.
- Margin depends more on manufacturing utilization, procurement contracts, and shortage conditions than on clinical innovation.
- The premixed plastic-container presentation may command operational value over a vial requiring pharmacy preparation, but that advantage is constrained by hospital contracts and generic competition.
No public filing provides a defensible product-level revenue series for PRIMACOR in Dextrose 5%. Any precise revenue estimate would require third-party prescription, hospital purchasing, or invoice data that is not contained in FDA labeling or public company reporting.
The product’s likely financial profile is therefore:
| Period |
Financial characterization |
| Launch and early commercialization |
Branded hospital product with differentiated formulation and clinical adoption |
| Post-generic period |
Declining brand economics and lower pricing power |
| Mature market |
Stable but modest institutional demand |
| Shortage periods |
Temporary volume and price opportunities for available suppliers |
| Long-term outlook |
Low growth, limited innovation, continued dependence on supply execution |
When did PRIMACOR lose exclusivity?
The active ingredient, milrinone, is an old small molecule. Any original compound or basic formulation exclusivity associated with the branded product has expired. PRIMACOR is not protected today by a conventional new-molecule exclusivity position.
FDA’s Orange Book should be reviewed for current patent and exclusivity entries associated with the relevant PRIMACOR new drug application. For an older product of this type, the commercial issue is generally not patent exclusivity but whether approved generic suppliers have active marketing authorizations for the same dosage form and route.
| Exclusivity category |
Current commercial relevance |
| New chemical entity exclusivity |
Expired |
| Original branded patent estate |
Expired or no longer commercially controlling |
| Pediatric exclusivity |
Not a current market barrier |
| Orphan-drug exclusivity |
Not the principal basis of market protection |
| Formulation exclusivity |
No known current barrier controlling generic access |
| Regulatory exclusivity for premixed presentation |
Not generally sufficient to block competing milrinone products |
What patents protect PRIMACOR in Dextrose 5%?
The current patent position is weak relative to newer branded drugs. The likely historical protection categories included:
- Milrinone compound patents.
- Pharmaceutical composition patents.
- Injectable formulation patents.
- Packaging or container patents.
- Manufacturing and stability claims.
Those categories do not create a meaningful present-day barrier to generic milrinone supply unless a specific, unexpired patent is listed against an approved application and covers the competing product’s formulation or use.
For an older premixed infusion, commercial protection is more likely to arise from know-how than enforceable patent rights. Relevant know-how can include:
- Sterile manufacturing parameters.
- Compatibility with plastic container materials.
- Control of adsorption and extractables.
- Solution stability.
- Terminal sterilization or aseptic-processing conditions.
- Container-closure integrity.
- Transportation and storage controls.
These manufacturing factors can increase development cost without creating a durable monopoly.
Are formulation patents important for the plastic-container presentation?
Formulation and container patents could historically have protected the premixed product, particularly where they claimed concentration, dextrose compatibility, pH, stability, or container construction. Their current value depends on expiration status and claim scope.
A generic manufacturer does not necessarily need to copy the branded container or manufacturing process. It can pursue a different formulation, package configuration, or process if the resulting product satisfies FDA requirements and avoids enforceable claims.
The practical barrier is regulatory equivalence and validated sterile production, not brand-specific formulation exclusivity.
Are there method-of-use patents for milrinone?
Method-of-use patents are unlikely to create a material barrier for the core hospital market. Milrinone’s principal use in short-term treatment of acute decompensated heart failure is well established and predates modern patent-law strategies used for newer therapies.
A later patent could theoretically address a specific dosing regimen, patient subgroup, combination, or treatment protocol. Such a patent would need to be valid, enforceable, and relevant to the labeling or use of the competing product. No such patent is known to provide broad market control over conventional PRIMACOR in Dextrose 5% use.
What is the Orange Book status of PRIMACOR?
The Orange Book is the central FDA source for approved drug applications, therapeutic-equivalence evaluations, and listed patent or exclusivity information. PRIMACOR is associated with milrinone lactate injection and an NDA held historically by the branded-product sponsor.
The relevant Orange Book questions are:
- Whether the reference listed drug remains actively marketed.
- Which NDA presentation corresponds to the premixed dextrose plastic container.
- Whether any patents remain listed.
- Which ANDAs have therapeutic-equivalence ratings.
- Whether the reference product has been discontinued for reasons other than safety or effectiveness.
The commercial significance of an Orange Book entry may differ from the label’s current market availability. A product can remain an FDA reference product for regulatory purposes even if the branded presentation is no longer widely sold.
Which companies are challenging PRIMACOR?
The market challenge is primarily generic and procurement-based rather than litigation-based. Generic companies compete through ANDA approvals, hospital contracts, shortage response, and manufacturing reliability.
Potential competitive groups include:
- Large injectable manufacturers.
- Hospital-focused generic suppliers.
- Contract manufacturers.
- Regional suppliers specializing in sterile products.
- Compounding pharmacies in limited circumstances, subject to applicable federal and state requirements.
There is no broad, high-value patent dispute associated with the conventional PRIMACOR premixed presentation comparable to litigation surrounding newer oncology, immunology, or metabolic drugs.
What patent litigation affects PRIMACOR?
No major active patent litigation is publicly associated with the core PRIMACOR in Dextrose 5% plastic-container market based on the product’s age and genericized status. The absence of visible litigation is commercially important: it indicates that market access is determined mainly by FDA approval, supply capacity, and contracts rather than by Paragraph IV litigation.
Are there Paragraph IV challenges?
Paragraph IV litigation is not expected to be a significant current factor for this mature milrinone product. Paragraph IV certifications are used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For an old injectable product with expired primary protection and limited current patent activity, the principal generic-entry pathway is likely ordinary ANDA approval rather than high-value patent litigation.
What FDA regulatory issues affect the product?
The key FDA issues are those that apply to sterile injectable products:
- Sterility assurance.
- Particulate control.
- Container-closure integrity.
- Stability through labeled storage conditions.
- Compatibility with infusion systems.
- Extractables and leachables from plastic containers.
- Manufacturing-site compliance.
- Labeling and concentration consistency.
- Adverse-event reporting.
- Shortage notification and supply continuity.
FDA’s Drug Shortages database is commercially relevant because injectable products can experience disruptions caused by raw-material constraints, manufacturing deviations, facility shutdowns, or limited reserve capacity (FDA, n.d.-b).
The product’s premixed format can reduce pharmacy preparation steps, but it also requires the manufacturer to maintain validated stability and container performance over the full shelf life.
What generic entry risks exist?
Generic entry risk is high in the sense that the active ingredient and basic clinical use are mature and replicable. The risk to any individual supplier is moderated by manufacturing complexity and the relatively small number of qualified sterile-injectable producers.
| Risk |
Assessment |
| New generic approval |
High |
| Patent-based blocking risk |
Low |
| Price erosion |
High |
| Hospital substitution |
High |
| Supply disruption |
Moderate to high |
| Competitor withdrawal |
Possible |
| Biosimilar competition |
Not applicable |
| Brand relaunch potential |
Low |
Generic entry does not necessarily produce continuous price decline. If several suppliers remain active, prices tend to be compressed. If suppliers withdraw or encounter manufacturing problems, remaining manufacturers can gain temporary volume and pricing leverage.
Is biosimilar risk relevant to PRIMACOR?
No. Milrinone is a chemically synthesized small molecule, not a biologic. Biosimilar regulation does not apply. Competition occurs through conventional generic-drug approval pathways, principally ANDAs and therapeutic-equivalence determinations.
What manufacturing and intellectual-property barriers remain?
The most important barriers are operational:
- Qualified sterile fill-finish facilities.
- Validated aseptic processing.
- Reliable milrinone active pharmaceutical ingredient supply.
- Plastic-container production and testing.
- Stability data for the premixed solution.
- FDA-compliant quality systems.
- Hospital-vendor qualification.
- Ability to maintain supply during shortages.
These barriers create entry friction but do not confer the pricing power associated with patent exclusivity. A new entrant must also demonstrate enough volume to justify development, regulatory, and commercial costs in a low-price market.
How does PRIMACOR compare with other hospital inotropes?
| Product |
Active ingredient |
Market structure |
Patent risk |
Main commercial distinction |
| PRIMACOR |
Milrinone |
Mature branded and generic injectable market |
Low |
PDE-3 inhibition; premixed availability |
| Dobutamine injection |
Dobutamine |
Mature generic hospital market |
Low |
Beta-adrenergic inotrope |
| Digoxin injection |
Digoxin |
Mature generic market |
Low |
Different mechanism and clinical profile |
| Levosimendan, where available |
Levosimendan |
Country-specific branded or limited market |
Varies by jurisdiction |
Not broadly interchangeable in the U.S. |
Milrinone competes clinically with other inotropes, but products are not interchangeable solely on price. Prescribing depends on hemodynamics, renal function, arrhythmia risk, blood pressure, and institutional protocols.
What licensing deals affect PRIMACOR?
No major current licensing transaction is publicly identified as controlling the commercial market for PRIMACOR in Dextrose 5%. The historical branded product may have involved manufacturing, distribution, or corporate portfolio arrangements, but current value is more likely captured through generic supplier contracts and hospital purchasing agreements.
Potential transaction value is concentrated in:
- Acquisition of approved injectable ANDAs.
- Purchase of sterile manufacturing capacity.
- Licensing of container technology.
- Regional distribution rights.
- Supply agreements with hospitals or GPOs.
A transaction involving this product would likely be evaluated as part of a broader injectable portfolio rather than as a standalone growth asset.
What are the likely launch scenarios for a new generic?
A new generic entrant would face three plausible scenarios:
Base case
The entrant obtains FDA approval, secures limited hospital contracts, and captures share through competitive pricing. Revenue grows gradually but margins remain constrained.
Supply-disruption case
Existing suppliers experience shortages or facility interruptions. The new entrant gains rapid institutional adoption and may achieve stronger pricing during the disruption.
Low-volume case
The product receives approval but fails to secure sufficient contracts because incumbent suppliers offer lower prices or broader portfolios. Revenue remains below commercial expectations.
The most valuable differentiator is dependable supply. A marginally lower price is less compelling to hospitals than a supplier with repeated backorders or incomplete container presentations.
What is the long-term commercial outlook?
The long-term outlook is stable to declining in nominal brand value, with periodic upside from shortages. PRIMACOR in Dextrose 5% is unlikely to generate material growth through price increases, new indications, or patent extensions. Its value lies in recurring hospital demand, established clinical use, and the operational convenience of a premixed infusion.
The product remains commercially relevant because acute-care hospitals require dependable access to injectable cardiovascular medicines. Its financial performance, however, is governed by generic economics and supply execution rather than innovation or exclusivity.
Key Takeaways
- PRIMACOR in Dextrose 5% is a premixed milrinone lactate intravenous product for short-term hospital treatment of acute decompensated heart failure.
- The product has mature, genericized market economics.
- No current patent barrier is expected to block conventional generic milrinone competition.
- Biosimilar risk does not apply because milrinone is a small-molecule drug.
- Product-level revenue is not publicly disclosed by Sanofi or generic suppliers.
- The main commercial risks are price erosion, hospital contracting, sterile-manufacturing constraints, and supply interruptions.
- Premixed plastic-container presentations have operational value but limited durable pricing power.
- Future financial performance is more likely to be stable or declining, with temporary upside during shortages.
- The most defensible competitive asset is reliable sterile supply, not intellectual-property exclusivity.
FAQs
Is PRIMACOR in Dextrose 5% still a branded product?
PRIMACOR is the historical brand name for milrinone lactate injection. Current hospital use may rely on generic milrinone products that provide the same active ingredient in comparable presentations.
Is milrinone in dextrose therapeutically equivalent to PRIMACOR?
An FDA-approved generic product may be therapeutically equivalent to the reference product when it has the applicable FDA rating and matches the required dosage form, strength, route, and conditions of use. Container configuration and premixed status must be evaluated separately.
Does PRIMACOR have exclusivity against generic milrinone?
No current broad exclusivity position is expected to protect the active ingredient or conventional hospital use of milrinone. Generic competition is established.
Can a hospital substitute a milrinone vial for a premixed plastic container?
Clinical substitution depends on the product’s concentration, labeling, pharmacy procedures, infusion requirements, and institutional policy. A vial and a premixed bag may contain the same active ingredient but are not operationally identical.
What would increase the value of a PRIMACOR-related asset?
Value would increase through an approved premixed presentation, reliable shortage-resistant manufacturing, strong hospital contracts, multiple container sizes, and inclusion in a broader sterile-injectable portfolio. Patent extension alone is unlikely to drive meaningful value for this mature product.
References
-
U.S. Food and Drug Administration. (n.d.-a). PRIMACOR- milrinone lactate injection, solution: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-d). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Sanofi. (n.d.). Annual reports and financial information. https://www.sanofi.com/en/investors/financial-results-and-events/financial-results
